Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss [Seeking Alpha]
C4 Therapeutics, Inc. (CCCC)
NASDAQ:AMEX Investor Relations:
ir.chinacache.com
Company Research
Source: Seeking Alpha
CCCC's lead asset, cemsidomide, showed promising Phase 1 results in multiple myeloma and is advancing to pivotal Phase 2 and combination trials in 2026. Despite a net loss and heavy R&D spending, the company boasts a strong cash position and trades at a discount to sector peers, with limited pipeline premium. Key upcoming catalysts include the Phase 2 MOMENTUM trial and the Phase 1b combo study; I remain bullish on CCCC's upside potential at current levels. Md Ariful Islam/iStock via Getty Images Thesis C4 Therapeutics ( CCCC reported a GAAP EPS loss of -$0.44 for 3Q25. A figure that missed analyst estimates by about $0.03. Revenue, on the other hand, came in at $11.23 million, beating expectations by $4.95 million. It's a bit of nice This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article mysel
Show less
Read more
Impact Snapshot
Event Time:
CCCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CCCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CCCC alerts
High impacting C4 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CCCC
News
- C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.MarketBeat
- C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.MarketBeat
- C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewswire
- C4 Therapeutics files $400M mixed shelf offering [Seeking Alpha]Seeking Alpha
- C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswire
CCCC
Earnings
- 11/6/25 - Beat
CCCC
Sec Filings
- 11/21/25 - Form S-3
- 11/14/25 - Form SCHEDULE
- 11/6/25 - Form 10-Q
- CCCC's page on the SEC website